Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Gap Down – Should You Sell?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) gapped down before the market opened on Wednesday . The stock had previously closed at $11.0250, but opened at $10.45. Santen Pharmaceutical shares last traded at $10.52, with a volume of 123,600 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Santen Pharmaceutical Price Performance

The firm’s fifty day moving average is $11.04 and its two-hundred day moving average is $10.66. The firm has a market cap of $3.38 billion and a price-to-earnings ratio of 0.10.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan?based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over?the?counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post?operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.